Factor V: A combination of Dr Jekyll and Mr Hyde

Blood

Volumn 101, Issue 1, 2003, Pages 20-30

  Mann, Kenneth G ^a,b,c   Kalafatis, Michael ^a,b,c  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b CLEVELAND STATE UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; PROTEIN S;

BLOOD CLOTTING FACTOR 5 DEFICIENCY; FIBRINOLYSIS; GENE ACTIVATION; GENE INACTIVATION; GENE STRUCTURE; GLYCOSYLATION; HUMAN; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; STRUCTURE ANALYSIS; SULFATION; THROMBOSIS;

EID: 0037220079     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-01-0290     Document Type: Review

References (171)

1. Owren PA. Parahaemophila: Haemorrhagic diathesis due to absence of a previously unknown clotting factor. Lancet. 1947;1993:446-448.
2. Owren PA, Cooper T. Parahemophilia. Arch Intern Med. 1955;95:194-201.
3. Mann KG, Nesheim ME, Tracy PB. Molecular weight of undegraded plasma factor V. Biochemistry. 1981;20:28-33.
4. Nesheim ME, Foster WB, Hewick R, Mann KG. Characterization of factor V activation intermediates. J Biol Chem. 1984;259:3187-3196.
5. Suzuki K, Dahlbäck B, Stenflo J. Thrombincatalyzed activation of human coagulation factor V. J Biol Chem. 1982;257:6556-6564.
6. Kane WH, Majerus PW. Purification and characterization of human coagulation factor V. J Biol Chem. 1981;256:1002-1007.
7. Tracy PB, Eide LL, Bowe EJW, Mann KG. Radioimmunoassay of factor V in human plasma and platelets. Blood. 1982;60:59-63.
8. Tracy PB, Giles AR, Mann KG, Eide LL, Hoogendoom H, Rivard GE. Factor V (Quebec): A bleeding diathesis associated with a qualitative platelet factor V deficiency. J Clin Invest. 1984;74:1221-1228.
9. Janeway CM, Rivard GE, Tracy PB, Mann KG. Factor V Quebec revisited. Blood. 1996;87:3571-3578.
10. Hayward CP, Cramer EM, Kane WH, et al. Studies of a second family with the Quebec platelet disorder: Evidence that the degradation of the alpha-granule membrane and its soluble contents are not secondary to a defect in targeting proteins to alpha-granules. Blood. 1997;89:1243-1253.
11. Montefuso MC, Duga S, Asselta R, et al. A novel two base pair deletion in the factor V gene associated with severe factor V deficiency. Br J Hematol. 2000;111:1240-1246.
12. Guash JF, Cannegieter S, Reitsma PH, van't Veer-Korthof ET, Bertina RM. Severe coagulation factor V deficiency caused by a 4 bp deletion in the factor V gene. Br J Hematol. 1998;101:32-39.
13. Nesheim ME, Nichols WL, Cole TL, et al. Isolation and study of an acquired inhibitor of human coagulation factor V. J Clin Invest. 1986;77:405-415.
14. Camire RM, Pollak ES, Kaushansky K, Tracy PB. Secretable human platelet-derived factor V originates from the plasma pool. Blood. 1998;92:3035-3041.
15. Viskup RW, Tracy PB, Mann KG. The isolation of human platelet factor V. Blood. 1987;69:1188-1195.
16. Monkovic DD, Tracy PB. Functional characterization of human platelet-released factor V and its activation by factor Xa and thrombin. J Biol Chem. 1990;265:17132-17140.
17. Hayward CP, Warketin TE, Horsewood P, Kelton JG. Multimerin: A series of large disulfide-linked multimeric proteins within platelets. Blood. 1991;77:2556-2560.
18. Hayward CP, Bainton DF, Smith JW, et al. Multimerin is found in the alpha-granules of resting platelets and is synthesized by a megakaryocytic cell line. J Clin Invest. 1993;91:2630-2639.
19. Hayward CP, Hassel JA, Denomme GA, Rachubinski RA, Brown C, Kelton JG. The cDNA sequence of human endothelial cell multimerin: A unique protein with RGDS, coiled-coil, and epidermal growth factor-like domains and a carboxyl terminus similar to the globular domain of complement C1q and collages type VIII and X. J Biol Chem. 1995;270:18246-18251.
20. Hayward CP, Furmaniak-Kazmierczack E, Cieutat AM, et al. Factor V is complexed with multimerin in resting platelet lysates and colocalizes with multimerin in platelet alpha-granules. J Biol Chem. 1995;270:19217-19224.
21. Cui J, O'Shea KS, Purkayastha A, Saunders TL, Ginsburg D. Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature. 1996;384:66-68.
22. 221-to-Val substitution results in reduced cofactor activity. Blood. 1995;86:1820-1827.
23. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90:1004-1008.
24. Reitsma PH, Poort SR, Allaart CF, Briet E, Bertina RM. The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: Heterogeneity and founder effects. Blood. 1991;78:890-894.
25. Cripe LD, Moore KD, Kane WH. Structure of the gene for human coagulation factor V. Biochemistry. 1992;31:3777-3785.
26. Jenny RJ, Pittman DD, Toole JJ, et al. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci U S A. 1987;84:4846-4850.
27. Kane WH, Ichinose A, Hagen FS, Davie EW. Cloning of cDNAs coding for the heavy chain region and connecting region of human Factor V, a blood coagulation factor with four types of internal repeats. Biochemistry. 1987;26:6508-6514.
28. Kane WH, Davie EW. Blood coagulation factors V and VIII: Structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood. 1988;71:539-555.
29. Cerveny TJ, Fass DN, Mann KG. Synthesis of coagulation Factor V by cultured aortic endothelium. Blood. 1984;63:1467-1474.
30. Wilson DB, Salem HH, Mruk JS, Maruyama I, Majerus PW. Biosynthesis of coagulation factor V by a human hepatocellular carcinoma cell line. J Clin Invest. 1984;73:654-658.
31. Chiu HC, Schick P, Colman R. Biosynthesis of factor V in isolated guinea pig megakaryocytes. J Clin Invest. 1985;75:339-346.
32. Mann KG, Lawler CM, Vehar GA, Church WR. Coagulation factor V contains copper ions. J Biol Chem. 1984;259:12949-12951.
33. Hortin GL. Sulfation of tyrosine residues in coagulation factor V. Blood. 1993;76:946-952.
34. Pittman DD, Tomkinson KN, Michnick D, Selighsohn U, Kaufman RJ. Posttranslational sulfation of factor V is required for efficient thrombin cleavage and activation and for full procoagulant activity. Biochemistry. 1994;33:6952-6959.
35. Pittman DD, Tomkinson KN, Kaufman RJ. Posttranslational requirement for functional factor V and factor VIII secretion in mammalian cells. J Biol Chem. 1994;269:17329-17337.
36. Kalafatis M, Rand MD, Jenny RJ, Ehrlich YH, Mann KG. Phosphorylation of factor Va and factor VIIIa by activated platelets. Blood. 1993;81:704719.
37. Rand MD, Kalafatis M, Mann KG. Platelet coagulation factor Va: The major secretory platelet phosphoprotein. Blood. 1994;83:2180-2190.
38. Kalafatis M. Identification and partial characterization of factor Va heavy chain-kinase from human platelets. J Biol Chem. 1998;273:8459-8466.
39. Kumar HPM, Besman MJ, Lundblad RL, Jenny NS, Mann KG. Carbohydrate analysis of plasma factor V and factor VIII. Thromb Haemost [Abstract]. 1999;Suppl 82:102a.
40. Singh LS, Kalafatis M. Sequencing of full-length cDNA encoding the α and β subunits of human casein kinase II from human platelets and megakaryocytic cells: Expression of casein kinase IIα intronless gene in a megakaryocytic cell line. Biochemistry. 2002;41:8935-8940.
41. Xue J, Kalafatis M, Mann KG. Determination of the disulfide bridges in factor Va light chain. Biochemistry. 1993;32:5917-5923.
42. Xue J, Kalafatis M, Silveira JR, Kung C, Mann KG. Determination of the disulfide bridges in factor Va heavy chain. Biochemistry. 1994;33:13109-13116.
43. Villoutreix BO, Dahlback B. Structural investigation of the A domains of human blood coagulation factor V by molecular modeling. Protein Sci. 1998;7:1317-1325.
44. Pellequer JL, Gale AJ, Getzoff ED, Griffin JH. Three-dimensional model of coagulation factor Va bound to activated protein C. Thromb Haemost. 2000;84:849-857.
45. Zaitseva I, Zaitsev V, Card G, et al. The X-ray structure of human serum ceruloplasmin at 3.1 Å: Nature of the copper centers. J Biol Inorg Chem. 1996;1:15-23.
46. Macedo-Ribeiro S, Bode W, Huber R, et al. Crystal structures of the membrane-binding C2 domain of human coagulation factor V. Nature. 1999;402:434-439.
47. aeffects of proteolytic cleavage on intramolecular association, intermolecular complex assembly and cofactor function [Doctoral Thesis]. Burlington, VT: University of Vermont, Department of Biochemistry; 2000.
48. Everse SJ, Adams TE. Crystal structure of bovine factor Va. Abstracts Junior Faculty Scholar 43rd Annual Meeting of the American Society of Hematology. Washington, DC: American Society of Hematology; 2001:66.
49. Nesheim ME, Taswell JB, Mann KG. The contribution of bovine factor V and factor Va to the activity of prothrombinase. J Biol Chem. 1979;254:10952-10962.
50. Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood coagulation. J Biol Chem. 2002;277:1832218333.
51. Butenas S, Brummel KE, Branda RF, Paradis SG, Mann KG. Mechanism of factor Vlla-dependent coagulation in hemophilia blood. Blood. 2002;99:923-930.
52. Butenas S, van't Veer C, Mann KG. Evaluation of the initiation phase of blood coagulation using ultra sensitive assays for serine proteases. J Biol Chem. 1997;272:21527-21533.
53. Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood. 2002;100:148-152.
54. Krishnaswamy S, Russel GD, Mann KG. The reassociation of factor Va from its isolated subunits. J Clin Invest. 1989;264:3160-3168.
55. Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin, I: An empirical study. J Biol Chem. 1994;269:23357-23366.
56. Rand MD, Lock JB, van't Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered blood. Blood. 1996;88:3432-3445.
57. van't Veer C, Mann KG. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. J Biol Chem. 1997;272:4367-4377.
58. Lee CD, Mann KG. Activation/inactivation of human factor V by plasmin. Blood. 1989;73:185-190.
59. Omar MN, Mann KG. Inactivation of factor Va by plasmin. J Biol Chem. 1987;262:9750-9755.
60. Kalafatis M, Mann KG. The role of the membrane in the inactivation of factor Va by plasmin: Amino acid region 307-348 of factor V plays a critical role for factor Va cofactor function. J Biol Chem. 2001;276:18614-18623.
61. +-dependent complex of fragments bound to phospholipid. J Biol Chem. 2001;276:19929-19936.
62. Krishnaswamy S, Church WR, Nesheim ME, Mann KG. Activation of human prothrombin by human prothrombinase: Influence of factor Va on the reaction mechanism. J Biol Chem. 1987;262:3291-3299.
63. Nesheim ME, Mann KG. The kinetics and cofactor dependence of the two cleavages involved in prothrombin activation. J Biol Chem. 1983;258:5386-5391.
64. Rosing J, Tans G, Govers-Riemslag JW, Zwaal RF, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem. 1980;255:274-283.
65. Rosing J, Zwaal RF, Tans G. Formation of meizothrombin as intermediate in factor Xa-catalyzed prothrombin activation. J Biol Chem. 1986;261:4224-4228.
66. Doyle MF, Mann KG. Multiple active forms of thrombin. J Biol Chem. 1990;265:10693-10701.
67. Krishnaswamy S, Mann KG. The binding of factor Va to phospholipid vesicles. J Biol Chem. 1988;263:5714-5723.
68. Kalafatis M, Jenny RJ, Mann KG. Identification and characterization of a phospholipid-binding site of bovine factor Va. J Biol Chem. 1990;265:21580-21589.
69. Kalafatis M, Rand MD, Mann KG. Factor Vamembrane interaction is mediated by two regions located on the light chain of the cofactor. Biochemistry. 1994;33:486-493.
70. Ortel TL, Quin-Allen MA, Keller FG, Peterson JA, Larocca D, Kane WH. Localization of functionally important epitopes within the second C-type domain of coagulation factor V using recombinant chimeras. J Biol Chem. 1994;269:15898-15905.
71. Ortel TL, Quinn-Allen MA, Charles LA, DevoreCarter D, Kane WH. Characterization of an acquired inhibitor to coagulation factor V: Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity. J Clin Invest. 1992;90:2340-2347.
72. Lecompte MF, Bouix G, Mann KG. Electrostatic and hydrophobic interactions are involved in factor Va binding to membranes containing acidic phospholipid. J Biol Chem. 1994;269:1905-1910.
73. Kim SW, Quin-Allen MA, Camp JT, et al. Identification of functionally important amino acid residues within the C2-domain of human factor V using alanine-scanning mutagenesis. Biochemistry. 2000;39:1951-1958.
74. Izumi T, Kim SW, Greist A, et al. Fine mapping of inhibitory anti-factor V antibodies using factor V C2 domain mutants: Identification of two antigenic epitopes involved in phospholipid binding. Thromb Haemost. 2001;85:1048-1054.
75. Krishnaswamy S, Jones KC, Mann KG. Prothrombinase complex assembly: Kinetic mechanism of enzyme assembly on phospholipid vesicles. J Biol Chem. 1988;263:3823-3834.
76. Bevers EM, Comfurius P, Zwaal RFA. Changes in membrane phospholipid distribution during platelet activation. Biochem Biophys Acta. 1983;736:57-66.
77. Bevers EM, Comfurius P, VanRijn JLML, Hemker HC, Zwaal RFA. Generation of prothrombinconverting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem. 1982;122:429-436.
78. Toti F, Satta N, Fressinaud E, Meyer D, Freyssinet JM. Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood. 1996;87:1409-1415.
79. Tracy PB, Mann KG. Prothrombinase complex assembly on the platelet surface is mediated through the 74,000-dalton component of factor Va. Proc Natl Acad Sci U S A. 1983;80:2380-2384.
80. Smirnov MD, Ford DA, Esmon CT, Esmon NL. The effect of membrane composition on the hemostatic balance. Biochemistry. 1999;38:3591-3598.
81. Krishnaswamy S, Mann KG, Nesheim ME. The prothrombinase-catalyzed activation of prothrombin proceeds through the intermediate meizothrombin in an ordered, sequential reaction. J Biol Chem. 1986;261:8977-8984.
82. Krishnaswamy S. Prothrombinase complex assembly: Contributions of protein-protein and protein-membrane interactions toward complex formation. J Biol Chem. 1990;265:3708-3718.
83. Tucker MM, Nesheim ME, Mann KG. Differentiation of enzyme and substrate binding in the prothrombinase complex. Biochemistry. 1983;22:4540-4546.
84. Kung C, Hayes E, Mann KG. A membranemediated catalytic event in prothrombin activation. J Biol Chem. 1994;269:25838-25848.
85. Pryzdial ELG, Mann KG. The association of coagulation factor Xa and factor Va. J Biol Chem. 1991;266:8969-8977.
86. Kalafatis M, Xue J, Lawler CM, Mann KG. Contribution of the heavy and light chains of factor Va to the interaction with factor Xa. Biochemistry. 1994;33:6538-6545.
87. Doyle MF, Haley PE. Meizothrombin: Active intermediate formed during prothrombinase-catalyzed activation of prothrombin. Methods Enzymol. 1993;222:299-312.
88. Bosckovic DS, Bajzar LS, Nesheim ME. Channeling during prothrombin activation. J Biol Chem. 2001;276:28686-28693.
89. Wu JR, Zhouu C, Majumder R, Powers DD, Weinreb G, Lentz BR. Role of procoagulant lipids in human prothrombin activation. 1. Prothrombin activation by factor Xa in the absence of factor Va and in the absence and presence of membranes. Biochemistry. 2002;41:935-949.
90. Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem. 1994;269:18735-18738.
91. Lu D, Kalafatis M, Mann KG, Long GL. Comparison of activated protein C/protein S-mediated activation of human factor VIII and factor V. Blood. 1996;87:4708-4717.
92. Esmon CT. The regulation of natural anticoagulant pathways. Science. 1987;235:1348-1352.
93. Lollar P, Parker C. pH-dependent denaturation of thrombin-activated porcine factor VIII. J Biol Chem. 1990;265:1688-1692.
94. Fay PJ, Haidaris PJ, Smudzin TM. Human factor VIIIa subunit structure: Reconstitution of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J Biol Chem. 1991;266:8957-8962.
95. Kalafatis M, Mann KG. Role of the membrane in the inactivation of factor Va by activated protein C. J Biol Chem. 1993;268:27246-27257.
96. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994;269:31869-31880.
97. Nicolaes GAF, Tans G, Thomassen MCLGD, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem. 1995;270:21158-21166.
98. Owen WG, Esmon CT. Functional properties of an endothelial cell cofactor for thrombincatalyzed activation of protein C. J Biol Chem. 1981;256:5532-5535.
99. Suzuki K, Kusumoto H, Deyashiki Y, et al. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J. 1987;6:1891-1897.
100. Krishnaswamy S, Williams EB, Mann KG. The binding of activated protein C to factor V and Va. J Biol Chem. 1986;261:9684-9693.
101. Hockin MF, Cawthern KM, Kalafatis M, Mann KG. A model describing the inactivation of factor Va by activated protein C (APC): Bond cleavage, fragment dissociation and product inhibition. Biochemistry. 1999;38:6918-6934.
102. Solymoss S, Tucker MM, Tracy PB. Kinetics of inactivation of membrane-bound factor Va by activated protein C: Protein S modulates factor Xa protection. J Biol Chem. 1988;263:14884-14890.
103. Nesheim ME, Canfield WM, Kisiel W, Mann KG. Studies of the capacity of factor Xa to protect factor Va from inactivation by activated protein C. J Biol Chem. 1982;257:1443-1447.
104. Mann KG, Hockin MF, Begin KJ, Kalafatis M. Activated protein C cleavage of factor Va leads to dissociation of the A2 domain. J Biol Chem. 1997;272:20678-20683.
105. Hockin MF, Kalafatis M, Shatos MA, Mann KG. Protein C activation and factor Va inactivation on human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol. 1997;17:2765-2775.
106. Hockin MF, Kalafatis M, Cawthern KM, Simoni P, Mann KG. A novel cellular mechanism for factor Va inactivation. 40th Annual Meeting of the American Society of Hematology. Blood. 1998;92(suppl 1):739a.
107. Undas A, Brummel K, Musial J, Mann KG, Szczeklik A. PI(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation. 2001; 104:2666-2672.
108. Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost. 1999;82:165-174.
109. Butenas S, van't Veer C, Mann KG. "Normal" thrombin generation. Blood. 1999;94:2169-2178.
110. Foster DC, Yoshitake S, Davie EW. The nucleotide sequence of the gene for human protein C. Proc Natl Acad Sci U S A. 1985;82:4673-4677.
111. Patracchini P, Aiello V, Palazzi P, ClzolarE, Bernardi F. Sublocalization of the human protein C gene on chromosome 2q13-q14. Hum Genet. 1989;81:191-192.
112. Reitsma PH. Protein C deficiency: From gene defects to disease. Thromb Haemost. 1997;78:344350.
113. R-1L/propeptide). Thromb Haemost. 2001;86:1017-1022.
114. Branson HE, Katz J, Marble R, Griffin JH. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet. 1983;19:1165-1168.
115. Estelles A, Garcia Plaza I, Dasi A, et al. Severe inherited "homozygous" protein C deficiency in a newborn infant. Thromb Haemost. 1984;52:5356.
116. Seligsohn U, Berger A, Abend M, et al. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med. 1984;310:559-562.
117. Odegaard B, Mann KG. Proteolysis of factor Va by factor Xa and activated protein C. J Biol Chem. 1987;262:11233-11238.
118. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
119. R506Q. J Biol Chem. 1995;270:4053-4057.
120. Kalafatis M, Haley PE, Lu D, Bertina RM, Long GL, Mann KG. Proteolytic events that regulate factor V activity in whole plasma from normal and activated protein C (APC)-resistant individuals during clotting: An insight into the APC-resistance assay. Blood. 1996;87:4695-4707.
121. R506Q by activated protein C. J Biol Chem. 1995;270:27852-27858.
122. Heeb MJ, Kojima Y, Greengard JS, Griffin JH. Activated protein C resistance: Molecular mechanisms based on studies using purified Gln506factor V. Blood. 1995;85:3405-3411.
123. Aparicio C, Dahlbäck B. Molecular mechanisms of activated protein C resistance. Biochem J. 1996;313:467-472.
124. Egan JO, Kalafatis M, Mann KG. The effect of Arg306→Ala and Arg506→Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S. Protein Sci. 1997;6:2016-2027.
125. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, Tracy PB. The mechanism of inactivation of platelet-derived factor Va from normal and APC-resistant individuals by activated protein C. J Biol Chem. 1995;270:20794-20800.
126. Leiden cofactor activities are sustained on the surface of activated platelets despite the presence of activated protein C. Blood. 1998;91:2818-2829.
127. Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: A new mutation (Arg306→Thr) associated with resistance to activated protein C. Blood. 1998;91:1140-1144.
128. Chan WP, Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood. 1998;91:1135-1139.
129. Koster T, Rosendaal FR, de Ronde H, Brie TE, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet. 1993;342:1503-1506.
130. Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506→Gln mutation in factor Va. Lancet. 1994;343:1362-1363.
131. Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point mutation at Arg506 of factor V. Lancet. 1994;343:1535-1536.
132. Sun X, Evatt B, Griffin JH. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood. 1994;83:3120-3125.
133. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 1994;343:1536-1538.
134. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504-1508.
135. Tripodi A, Mannucci PM. Laboratory investigation of thrombophilia. Clin Chem. 2001;47:1597-1606.
136. Lillicrap D. The genetics of venous and arterial thromboembolism. Curr Atheroscler Rep. 2001;3:209-215.
137. Segel GB, Francis CW. Anticoagulant proteins in childhood venous and arterial thrombosis: A review. Blood Cells Mol Dis. 2000;26:540-560.
138. Gladson CL, Scharrer I, Hach V, Beck KH, Griffin JH. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost. 1988;59:18-22.
139. Reitsma PH, Poort SR, Allaart CF, Briet E, Bertina RM. The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: Heterogeneity and founder effects. Blood. 1991;78:890-894.
140. Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briet E. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet. 1993;341:134-138.
141. Bertina RM. Protein C deficiency and venous thrombosis - The search for the second genetic defect. Thromb Haemost. 2000;83:360-361.
142. Ozbek N, Tokel NK, Kayiran SM. Inherited combined deficiency of protein C and S. Eur J Haematol. 1999;63:138-139.
143. Bernardi F, Faioni EM, Castoldi E, et al. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood. 1997;90:1552-1557.
144. Lunghi B, Iacoviello L, Gemmati D, et al. Detection of new polymorphic markers in the factor V gene: Association with factor V levels in plasma. Thromb Haemost. 1996;75:45-48.
145. Castoldi E, Rosing J, Girelli D, et al. Mutations in the R2FV gene affect the ratio between the two isoforms in plasma. Thromb Haemost. 2000;83:362-365.
146. Alhenc-Gelas M, Nicaud V, Gandrille S, et al. The factor V gene A4070G mutation and the risk of venous thrombosis. Thromb Haemost. 1999;81:193-197.
147. Castoldi E, Simioni P, Kalafatis M, et al. Combinations of four mutations (FVR506Q, FV H1299R, FVY 1702C, PT20210G/A) affecting the prothrombinase complex in a thrombophilic family. Blood. 2000;96:1443-1448.
148. Kalafatis M, Simioni P, Bernardi F. Phenotype and genotype expression in pseudohomozygous R2 factor V. Blood. 2001;98:1988-1989.
149. Gemmati D, Serino ML, Moratelli S, Mari R, Ballerini G, Scapoli GL. Coexistence of antithrombin deficiency, factor V Leiden and hyperhomocystinemia in a thrombotic family. Blood Coagul Fibrinolysis. 1998;9:173-176.
150. Kluijtmans LA, Boers GH, Verbruggen B, Trijbels FJ, Novakova IR, Blomm HJ. Homozygous cystathionine beta-synthase deficiency, combined with factor V Leiden or thermolabile methylenetetrahydrofolate reductase in the risk of venous thrombosis. Blood. 1998;91:2015-2018.
151. Undas A, Williams EB, Butenas S, Orfeo T, Mann KG. Homocysteine inhibits inactivation of factor Va by activated protein C. J Biol Chem. 2001;276:4389-4397.
152. Nesheim ME, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Hemost. 1997;78:386-391.
153. Bajzar L, Nesheim ME. The effect of activated protein C on fibrinolysis in cell-free plasma can be attributed specifically to attenuation of prothrombin activation. J Biol Chem. 1993;268:8608-8616.
154. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem. 1995;270:14477-14484.
155. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem. 1998;273:27176-27181.
156. LEIOEN. J Biol Chem. 1996;271:22949-22952.
157. Broze GJ Jr, Higuchi D. Coagulation-dependent inhibition of fibrinolysis: Role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood. 1996;88:3815-3823.
158. Broze GJ Jr, Lange GW, Duffin KL, MacPhail L. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis. 1994;5:551559.
159. Broze GJ Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Ann Rev Med. 1995;46:103-112.
160. Huang Z, Wun T, Broze GJ Jr. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem. 1993;268:26950-26955.
161. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem. 1989;264:18832-18837.
162. van't Veer C, Golden NJ, Kalafatis M, Mann KG. Inhibitory mechanism of the protein C pathway on tissue factor induced thrombin generation. Synergistic effect in combination with tissue factor pathway inhibitor. J Biol Chem. 1997;272:7983-7994.
163. LEIDEN. J Biol Chem. 1997;272:20721-20729.
164. Eitzman DT, Westrick RJ, Xiaming Bi, et al. Lethal perinatal thrombosis in mice resulting from the interaction of tissue factor pathway inhibitor deficiency and factor V Leiden. Circulation. 2002;105:2139-2142.
165. R506Q mutation. Blood. 1996;88:1183-1187.
166. 10400→T) and heterozygous factor V Leiden. Haemophilia. 2001;7:511-514.
167. Leiden and hemophilia A. Blood. 1997;90:3067-3072.
168. Simioni P, Scudeller A, Radossi P, et al. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: Report of two cases belonging to two unrelated kindreds. Thromb Haemost. 1996;75:422-426.
169. Zehnder JL, Jain M. Recurrent thrombosis due to compound heterozygosity for factor V Leiden and factor V deficiency. Blood Coagul Fibrinolysis. 1996;7:361-362.
170. Guasch JF, Lensen RPM, Bertina RM. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is pseudo homozygous for activated protein C resistance. Thromb Haemost. 1997;77:252-257.
171. LEIDEN. The need for phenotype analysis. Arterioscler Thromb Vasc Biol. 1999;19:336-342.